AngioGenex and BioCheck in cancer testing deal
US firms AngioGenex and BioCheck have entered into an agreement to develop cancer diagnostic and prognostic products based on the Id-gene platform technology licensed exclusively to AGx by the Albert Einstein College of Medicine and the Memorial Sloan Kettering Cancer Center.
BioCheck and AGx, both privately-held companies, will apply their resources and expertise to develop diagnostics for early detection and prognosis of cancer based on the measurement of Id-proteins in blood and tumor tissue. A recently-approved Phase I SBIR grant will provide seed funding for the collaboration.
Partial loss of Id function leads to a profound resistance to the growth and metastasis of tumors in animals due to an inability to develop a supporting network of blood vessels (angiogenesis). In adults, the presence of Id proteins is associated with the formation of tumors.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze